SEATTLE, WA: January 17, 2019 – EMPOWER CLINICS INC. (CSE: EPW) (Frankfurt 8EC) (“Empower” or the “Company”) today provided a corporate update on operations and changes to its board of directors
The Company is pleased to announce its first production run of Sollievo CBD lotion has commenced selling in two test markets – Portland, OR and Seattle, WA. Initial product sales are direct to market both in Empower clinics located in the test markets and through other practitioners, such as chiropractors, health & fitness clubs and elder care facilities.
HOW IT WORKS: All Sollievo products are powered by 99% pure hemp CBD isolate and proprietary terpene blends. CBD (cannabidiol) is a non-psychoactive molecule found in hemp and cannabis plants. After multiple stages of refinement, CBD is purified into crystals (isolate) and other compounds like chlorophyll are removed.
Every Sollievo product uses CBD crystals combined with naturally derived terpene blends to address specific everyday ailments like chronic pain, insomnia, digestion issues, and anxiety. The blends are designed by top scientists in the hemp and cannabis industry to address the most common qualifying conditions of Empower Clinics patients and consumers.
Empower Clinics’ doctors advised a team of chemists, biologists and product designers in creating products that will never intoxicate you or leave you with a hangover. Currently, the Empower product development team has created numerous proprietary product blends and categories, in various stages of product analysis, packaging and roll-out, including CBD lotions, tinctures, spectrum oils, capsules, lozenges, patches and an eDrink.
“The passing of the US$867 billion Agriculture Improvement Act (the Farm Bill) has legalized hemp and hemp based products. This has created a massive opportunity for the production and sales of a variety of CBD based products that can provide genuine help and effective relief to millions of people suffering from a variety of serious qualifying conditions,” said Steven McAuley, Empower Chairman & CEO. He further states, “Recent reports and studies indicate the approval of this bill could create a US$20 billion industry by 2022.”
The Company would also like to announce the resignation of Mr. Dan Ballister as a director of Empower and thanks him for his service and support of the Company. The Company also announces the appointment of Ms. Emily Davis as a director of the Company. Ms. Davis brings extensive corporate and public company experience and will support the Company in this role as it continues to identify new candidates for its board of directors,
Empower is a leading owner/operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative uses of medical cannabis. Treatment solutions are focused on education, data and efficacy in combination with other modalities to support patients with serious qualifying conditions, such as chronic pain, PTSD, sleep disorders, opioid dependency, epilepsy and more. It is expected that Empower’s proprietary product line “Sollievo” will offer patients a variety of delivery methods of doctor recommended medical cannabis product options in its clinics, online and at major retailers. With over 120,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine and an expanded product development strategy, Empower believes it is positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond.
ON BEHALF OF THE BOARD OF DIRECTORS:
Chief Executive Officer
Boom Capital Markets firstname.lastname@example.org
This news release contains certain “forward-looking statements” or “forward-looking information” as contemplated by applicable Canadian securities law. Forward-looking statements are frequently characterized by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected availability of the Company’s clinics and products; the expected benefits of the Company’s products and that the Company is positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only a projection based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Company’s products may not work as expected; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.